Engineered Defensin-Albumin Fusion Protein Suppresses Cytokine Storms and Reduces Organ Damage in Mice
A fusion protein combining two human beta-defensin 2 molecules with albumin (DF2-HSA) reduced mortality, cytokine levels, vascular leakage, and lung/intestine damage in a cytokine storm mouse model.
Quick Facts
What This Study Found
DF2-HSA reduced mortality in a cytokine storm mouse model while prolonging HBD-2 retention, decreasing multiple inflammatory cytokines, reducing vascular leakage, and alleviating lung and intestinal tissue damage.
Key Numbers
How They Did This
LPS-induced cytokine storm model in BALB/c athymic mice, with Luminex cytokine profiling, Evans blue vascular permeability assay, transmission electron microscopy, and histopathological analysis.
Why This Research Matters
Cytokine storms remain a major cause of death in sepsis and severe viral infections. An engineered defensin that both fights infection and controls inflammation could address both aspects simultaneously.
The Bigger Picture
This fusion protein approach—combining antimicrobial and anti-inflammatory properties in one molecule with extended half-life—represents a sophisticated peptide engineering strategy for critical care applications.
What This Study Doesn't Tell Us
Mouse model using athymic mice. LPS-induced cytokine storm may not fully replicate human sepsis or viral-induced storms. Dosing optimization and safety profiling needed.
Questions This Raises
- ?Could DF2-HSA be effective in viral-induced cytokine storms (e.g., COVID-19)?
- ?What is the therapeutic window for DF2-HSA administration during a cytokine storm?
- ?How does DF2-HSA compare to existing anti-cytokine therapies like tocilizumab?
Trust & Context
- Key Stat:
- Dual action DF2-HSA combines HBD-2 antimicrobial activity with albumin's anti-inflammatory properties in a single long-acting molecule
- Evidence Grade:
- Preclinical study with comprehensive outcome assessment. Novel fusion protein approach but needs validation in more clinically relevant models.
- Study Age:
- Published in 2025.
- Original Title:
- A Human β-Defensin-Based Recombinant Protein DF2-HSA Ameliorates Cytokine Storm.
- Published In:
- Cells, 15(2) (2026)
- Authors:
- Du, Yibo(2), Yu, Zhuojun, Sheng, Weijin, Li, Yi, Hou, Lei, Zheng, Yanbo, Liu, Xiujun, Zhen, Yongsu
- Database ID:
- RPEP-15124
Evidence Hierarchy
Frequently Asked Questions
What is a cytokine storm?
A cytokine storm is when the immune system overreacts, flooding the body with inflammatory molecules that damage organs instead of fighting infection. It's a major cause of death in sepsis and severe COVID-19.
How does this peptide help?
DF2-HSA combines a human antimicrobial peptide (defensin) that fights infection with albumin that reduces inflammation and keeps the peptide active longer in the body—addressing both the infection and the harmful immune overreaction.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15124APA
Du, Yibo; Yu, Zhuojun; Sheng, Weijin; Li, Yi; Hou, Lei; Zheng, Yanbo; Liu, Xiujun; Zhen, Yongsu. (2026). A Human β-Defensin-Based Recombinant Protein DF2-HSA Ameliorates Cytokine Storm.. Cells, 15(2). https://doi.org/10.3390/cells15020202
MLA
Du, Yibo, et al. "A Human β-Defensin-Based Recombinant Protein DF2-HSA Ameliorates Cytokine Storm.." Cells, 2026. https://doi.org/10.3390/cells15020202
RethinkPeptides
RethinkPeptides Research Database. "A Human β-Defensin-Based Recombinant Protein DF2-HSA Amelior..." RPEP-15124. Retrieved from https://rethinkpeptides.com/research/du-2026-a-human-defensinbased-recombinant
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.